Managing Director and Chief Executive Officer Riccardo Canevari
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Radiopharm Theranostics (RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
  • Payment for the acquisition will consist of US$500,000 (A$696,088) in Radiopharm Theranostics shares
  • The company will acquire patents to three different nanobodies which target breast cancer and multiple solid tumours
  • Results from phase one clinical studies of RAD201 completed indicate the potential use of NanoMab’s nanobodies for imaging and treatment of HER-2 positive cancers with different medical radioisotopes
  • Shares finished the day of trading down 4.11 per cent to 35 cents

Radiopharm Theranostics (RAD) has acquired full intellectual property (IP) ownership to three assets to target diagnosis and treatment of a range of solid tumours from NanoMab Technology.

Payment for the acquisition will consist of US$500,000 (A$696,088) in Radiopharm Theranostics shares.

The company will acquire patents to three different nanobodies which target breast cancer and multiple solid tumours. This includes HER-2, TROP-2, and PTK7.

Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb), that can be labelled with radioisotopes to diagnose and treat multiple tumour types.

Radiopharm has been using NanoMab nanobodies under a licence agreement in its Phase one clinical trials and pre-clinical studies.

Results from phase one clinical studies of RAD201 indicate the potential use of NanoMab’s nanobodies for imaging and treatment of HER-2 positive cancers with different medical radioisotopes.

Final candidate selection for TROP2 and PTK7 is underway.

Managing Director and Chief Executive Officer Richard Canevari said the acquisition was based on the high potential of nanobody technology in both diagnostic and therapeutic applications.

“Acquiring the IP for these assets supports Radiopharm’s strategy to focus on innovation and it will allow us to further accelerate clinical development of these multiple assets,” he said.

“We are excited to build on our existing portfolio of worldwide IP rights with these assets from Nanomab Technology Ltd.”

Shares finished the day of trading down 4.11 per cent to 35 cents.

RAD by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…